ALLMedicine™ Mantle Cell Lymphoma Center
Research & Reviews 4,179 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919095
BMC Cancer; Assis-Mendonça GR, Fattori A et. al.
Mar 2nd, 2021 - There is evidence to consider that the tumor microenvironment (TME) composition associates with antitumor immune response, and may predict the outcome of various non-Hodgkin lymphoma subtypes. However, in the case of mantle cell lymphoma (MCL), a ...
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.
Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y
Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.
Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805338
Blood Advances; Maekawa F, Kishimori C et. al.
Feb 11th, 2021 - Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.|2021|Maekawa F,Kishimori C,Nakagawa M,Takeoka K,Fukutsuka K,|
Guidelines 13 results
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl
May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson,J.,et al
Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...
https://doi.org/10.1111/bjh.15283
British Journal of Haematology; McKay P, Leach M et. al.
May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.
Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,
Drugs 25 results see all →
Clinicaltrials.gov 4,547 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919095
BMC Cancer; Assis-Mendonça GR, Fattori A et. al.
Mar 2nd, 2021 - There is evidence to consider that the tumor microenvironment (TME) composition associates with antitumor immune response, and may predict the outcome of various non-Hodgkin lymphoma subtypes. However, in the case of mantle cell lymphoma (MCL), a ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022
Mar 1st, 2021 - TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is approved under accelerated approval based on ...
https://doi.org/10.1111/bjh.17363
British Journal of Haematology; McCulloch R, Lewis D et. al.
Feb 23rd, 2021 - Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when give...
https://doi.org/10.1097/RLU.0000000000003597
Clinical Nuclear Medicine; Xu G, Lu Y
Feb 16th, 2021 - We present here a 72-year-old man with mantle cell lymphoma who has completed chemotherapy and achieved complete metabolic response to the therapy 10 months ago. Series follow-up FDG PET/CT scans have been negative for lymphoma. Current FDG PET/CT...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805322
Blood Advances; Wu W, Wang W et. al.
Feb 11th, 2021 - Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it i...
News 501 results
https://www.medscape.com/viewarticle/943428
Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...
https://www.medscape.com/viewarticle/939947
Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...
https://www.staging.medscape.com/viewarticle/939270
Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...
https://www.medscape.com/viewarticle/939270
Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...
https://www.staging.medscape.com/viewarticle/937175
Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...